Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
11/2002
11/28/2002US20020177213 Tissue plasminogen activator-like protease
11/28/2002US20020176912 Such as (6S)-tetrahydrofolic acid, and the 5-methyl, 5- or 10-formyl, 5,10-methylene, 5,10-methenyl, or 5-formimino derivatives; increasing folate intake such as to prevent birth defects
11/28/2002US20020176887 Methods of delivery of cetyl myristoleate
11/28/2002CA2449442A1 Combination medicament for treatment of neoplastic diseases
11/28/2002CA2448449A1 Treatment of renal fibrosis
11/28/2002CA2448120A1 Muscle-specific expression vectors
11/28/2002CA2448080A1 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
11/28/2002CA2448022A1 Compositions for protein delivery via the pulmonary route
11/28/2002CA2447942A1 A gene and uses therefor
11/28/2002CA2447340A1 Kinases and phosphatases
11/28/2002CA2447338A1 Receptors and membrane-associated proteins
11/28/2002CA2447236A1 Pulmonary administration of chemically modified insulin
11/28/2002CA2447170A1 Emulsion and dispersion formulations and method
11/28/2002CA2447103A1 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
11/28/2002CA2447020A1 The use of 4-aminopyridine derivatives for the treatment of mglur5 receptor mediated diseases
11/28/2002CA2446734A1 Antibodies against tumor necrosis factor delta (april)
11/28/2002CA2446324A1 Quinoline derivatives as ligands for the neuropeptide y receptor
11/28/2002CA2445631A1 Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same
11/28/2002CA2445010A1 Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors
11/28/2002CA2444955A1 Inactivation of genes of the mep pathway
11/28/2002CA2441801A1 Methods and formulations for increasing the affinity of a1 adenosine receptor ligands for the a1 adenosine receptor
11/27/2002EP1260502A1 Vitamin d derivatives having substituents at the 2alpha-position
11/27/2002EP1260228A2 Human growth gene and short stature gene region. Therapeutic uses
11/27/2002EP1260210A1 Squalane containing ultra fine particles of burning residue of carbon and method for producing the same
11/27/2002EP1259622A2 Nucleotide sequences encoding proteins that take part in the biosynthesis of l-serine, improved method for microbially producing l-serine, and genetically modified microorganism suitable for use in said method
11/27/2002EP1259621A2 Lipid metabolism enzymes
11/27/2002EP1259612A2 G-protein coupled receptor related polypeptides
11/27/2002EP1259611A2 G-protein coupled receptors
11/27/2002EP1259595A2 Integrin antagonists
11/27/2002EP1259527A1 35 human secreted proteins
11/27/2002EP1259523A2 Pluraflavins and derivatives thereof, process for their preparation and use thereof
11/27/2002EP1259520A2 Novel purines
11/27/2002EP1259505A2 Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same
11/27/2002EP1259504A1 Pyrazole ether derivatives as anti-inflammatory/analgesic agents
11/27/2002EP1259498A1 8,8a-dihydro-indeno 1,2-d]thiazole derivatives, substituted in position 8a, a method for their production and their use as medicaments, e.g. anorectic agents
11/27/2002EP1259494A1 Aryloxyacetic acids for diabetes and lipid disorders
11/27/2002EP1259492A1 Substituted piperazine derivatives as mtp inhibitors
11/27/2002EP1259489A1 Aryl fused azapolycyclic compounds
11/27/2002EP1259488A1 Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors
11/27/2002EP1259487A1 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
11/27/2002EP1259484A1 Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion
11/27/2002EP1259481A1 Substituted benzoylguanidines, method for their production, their use as a medicament or diagnostic agent and a medicament containing the same
11/27/2002EP1259474A1 Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
11/27/2002EP1259292A2 Therapeutic agents
11/27/2002EP1259246A2 Use of dpp-iv inhibitors for the treatment of diabetes
11/27/2002EP1259236A1 Tyrosine kinase inhibitors
11/27/2002EP1259234A1 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
11/27/2002EP1259224A2 Cochleate formulations and their use for delivering biologically relevant molecules
11/27/2002EP1259223A1 Protein matrix materials, devices and methods of making and using thereof
11/27/2002EP1259128A1 Water containing soluble fiber
11/27/2002EP1259125A1 Inulin products with improved nutritional properties
11/27/2002EP1259121A2 Weight loss induced by reduction in neuropeptide y level
11/27/2002EP1259112A1 Nutritional intervention composition for enhancing and extending satiety
11/27/2002EP1112005B1 Antioxidant composition comprising acetyl l-carnitine and alpha-lipoic acid
11/27/2002EP1089744B1 Neuroprotective composition for the prevention and/or treatment of nervous and behavioural alterations due to anxiety states or depression, comprising acetyl-l-carnitine and hypericin
11/27/2002EP1073639B1 Quinoline derivatives
11/27/2002EP1017672B1 New npy antagonists
11/27/2002EP1000048B1 Substituted 1,2,3,4-tetrahydronaphthalene derivatives
11/27/2002EP0977564A4 Forskohlin for promoting lean body mass
11/27/2002EP0814782B1 Pharmaceutical composition stabilized with a basic agent
11/27/2002EP0765330B1 Lactam inhibitors of cholesterol esterase
11/27/2002EP0708648B1 Inhibition of nitric oxide production by retinoic acid
11/27/2002EP0627933B1 Bystander suppression of autoimmune diseases
11/27/2002CN1382151A Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1-[4-(2-amin-1-yl-ethoxy)-benzyl)-1h-indol-5-ols
11/27/2002CN1382146A Imidazole derivatives asphosphodiesterase VII inhibitors
11/27/2002CN1382144A Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase
11/27/2002CN1382143A Inhibitors of alpha L beta 2 mediated cell adhesion
11/27/2002CN1382140A Neurotrophic pyrrolidines and piperidines and related compositions containing them
11/27/2002CN1382138A Piperidine derivatives as reuptake inhibitors
11/27/2002CN1382136A N-heterocyclic derivatives as NOS inhibitors
11/27/2002CN1382135A Amine and amide derivatives as ligands for neuropeptide YY5 receptor usefu in treatment of obesity and other disorders
11/27/2002CN1382131A Substituted benzylthiazolidine-2,4-dione derivatives
11/27/2002CN1382130A Substituted benzylthiazolidine-2,4-dione derivatives
11/27/2002CN1382129A Substituted benzylthiazolidine-2,4-dione derivatives
11/27/2002CN1382128A Substituted benzylthiazolidine-2,4-dione derivatives
11/27/2002CN1382122A Pyrrole derivatives as phosphodiesterase VII inhibitors
11/27/2002CN1382119A Substituted alpha hydroxy acid aspertate specific cysteine protease inhibitors and use thereof
11/27/2002CN1382118A Biocyclic amino acids aspharmaceutical agents
11/27/2002CN1382052A Use of dipyridazole or mopidamol in the manufacture of a medicament for treatment and prevention of fibrin-dependent microcirculation disorders
11/27/2002CN1382047A Neurotherapeutic clavulanate composition and method
11/27/2002CN1382043A Food materials useful in preventing and ameliorating metabolic bone diseases and preventives/remedies for metabolic bone diseases comprising these materials
11/27/2002CN1382041A Direct comperession polymer tablet core
11/27/2002CN1382036A Solubilized pharmaceutical composition for parenteral administration
11/27/2002CN1381584A Configuration of stable expression plasmid of insuline and process for efficient introduction to body
11/27/2002CN1381272A Application of insulinotropic peptide GLP-1 (7-36) and its solt
11/27/2002CN1381271A Application of insulinotropic peptide Exendin 4 analog and its salt
11/27/2002CN1381270A Ca-supplementing instant composite polypeptide powder and its preparing process
11/27/2002CN1381263A Weight-lossing hypolipemic medicine
11/27/2002CN1381246A Nutritive cactus tablet and its preparing process
11/27/2002CN1381245A Beautifying cactus tablet and its preparing process
11/27/2002CN1381236A Medicinal composition containing baicalin and caffoeoylchinic acid
11/27/2002CN1381204A Beverage prepared by microalternative bioelectric field for dredging blood vessel and reducing blood fat
11/27/2002CN1381203A Weight-lossing beverage prepared by microalternative bioelectric field
11/27/2002CN1094734C Method for preparing fatty acid ester and nutriment containing fatty acid ester
11/26/2002US6486305 Method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3
11/26/2002US6486299 Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
11/26/2002US6486205 Mixture of primary fatty acids obtained from sugar cane wax
11/26/2002US6486184 1-(cyclopentyloxy-(3,4-dichloro- phenyl)-acetyl)-3-methyl-urea for example; use in treating hyperglycemia characteristic of all type ii diabetes
11/26/2002US6486182 Mutual prodrugs of amlodipine and atorvastatin
11/26/2002US6486177 Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
1 ... 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 ... 1298